All these findings led to extensive investigations to evaluate the potential of DDR-targeting drugs for prostate and breast tumors which culminated in the approval of PARP-1 inhibitors for breast cancer and, very recently, also for prostate cancer [57,58,59]. This evidence concerns the gene PARP1 and breast cancer.